Company Overview of InteKrin Therapeutics Inc.
InteKrin Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for inflammatory and metabolic disorders. Its product includes INT-131, a peroxisome proliferator-activated receptor gamma modulator that targets inflammation and activates neuroprotective pathways. The company was founded in 2005 and is based in Redwood City, California. As of February 12, 2014, InteKrin Therapeutics Inc. operates as a subsidiary of Coherus Biosciences, Inc.
201 Redwood Shores Parkway
Redwood City, CA 94065
Founded in 2005
Key Executives for InteKrin Therapeutics Inc.
Similar Private Companies By Industry
|Pacific Pharmaceuticals||United States|
|Excaliard Pharmaceuticals, Inc.||United States|
|Mytogen, Inc.||United States|
|Arrogene, Inc.||United States|
|NGM Biopharmaceuticals, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact InteKrin Therapeutics Inc., please visit www.intekrin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.